483 related articles for article (PubMed ID: 31897900)
21. Changes in oestrogen receptor-alpha and -beta during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells.
Shaw LE; Sadler AJ; Pugazhendhi D; Darbre PD
J Steroid Biochem Mol Biol; 2006 Apr; 99(1):19-32. PubMed ID: 16533599
[TBL] [Abstract][Full Text] [Related]
22. STAT1 facilitates oestrogen receptor α transcription and stimulates breast cancer cell proliferation.
Hou Y; Li X; Li Q; Xu J; Yang H; Xue M; Niu G; Zhuo S; Mu K; Wu G; Li X; Wang H; Zhu J; Zhuang T
J Cell Mol Med; 2018 Dec; 22(12):6077-6086. PubMed ID: 30334368
[TBL] [Abstract][Full Text] [Related]
23. Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.
Thewes V; Simon R; Schroeter P; Schlotter M; Anzeneder T; Büttner R; Benes V; Sauter G; Burwinkel B; Nicholson RI; Sinn HP; Schneeweiss A; Deuschle U; Zapatka M; Heck S; Lichter P
Cancer Res; 2015 Feb; 75(4):720-31. PubMed ID: 25643697
[TBL] [Abstract][Full Text] [Related]
24. Protein phosphatase 1, regulatory subunit 15B is a survival factor for ERα-positive breast cancer.
Shahmoradgoli M; Riazalhosseini Y; Haag D; Becker N; Hovestadt V; Heck S; Sinn HP; Schneeweiss A; Mannherz O; Sahin Ö; Lichter P
Int J Cancer; 2013 Jun; 132(11):2714-9. PubMed ID: 23169272
[TBL] [Abstract][Full Text] [Related]
25. Bioactive dietary supplements reactivate ER expression in ER-negative breast cancer cells by active chromatin modifications.
Meeran SM; Patel SN; Li Y; Shukla S; Tollefsbol TO
PLoS One; 2012; 7(5):e37748. PubMed ID: 22662208
[TBL] [Abstract][Full Text] [Related]
26. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.
Jin K; Park S; Teo WW; Korangath P; Cho SS; Yoshida T; Győrffy B; Goswami CP; Nakshatri H; Cruz LA; Zhou W; Ji H; Su Y; Ekram M; Wu Z; Zhu T; Polyak K; Sukumar S
Cancer Discov; 2015 Sep; 5(9):944-59. PubMed ID: 26180042
[TBL] [Abstract][Full Text] [Related]
27. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.
Shah N; Jin K; Cruz LA; Park S; Sadik H; Cho S; Goswami CP; Nakshatri H; Gupta R; Chang HY; Zhang Z; Cimino-Mathews A; Cope L; Umbricht C; Sukumar S
Cancer Res; 2013 Sep; 73(17):5449-58. PubMed ID: 23832664
[TBL] [Abstract][Full Text] [Related]
28. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.
Millour J; Constantinidou D; Stavropoulou AV; Wilson MS; Myatt SS; Kwok JM; Sivanandan K; Coombes RC; Medema RH; Hartman J; Lykkesfeldt AE; Lam EW
Oncogene; 2010 May; 29(20):2983-95. PubMed ID: 20208560
[TBL] [Abstract][Full Text] [Related]
29. Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models.
Jones CJ; Subramaniam M; Emch MJ; Bruinsma ES; Ingle JN; Goetz MP; Hawse JR
Mol Cancer Res; 2021 Jun; 19(6):1026-1039. PubMed ID: 33627502
[TBL] [Abstract][Full Text] [Related]
30. Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells.
Lin JH; Tu SH; Chen LC; Huang CC; Chang HL; Cheng TC; Chang HW; Wu CH; Wu HC; Ho YS
Breast Cancer Res Treat; 2018 Nov; 172(1):45-59. PubMed ID: 30054830
[TBL] [Abstract][Full Text] [Related]
31. Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.
Notas G; Pelekanou V; Kampa M; Alexakis K; Sfakianakis S; Laliotis A; Askoxilakis J; Tsentelierou E; Tzardi M; Tsapis A; Castanas E
Mol Oncol; 2015 Nov; 9(9):1744-59. PubMed ID: 26115764
[TBL] [Abstract][Full Text] [Related]
32. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.
Chu J; Zhu Y; Liu Y; Sun L; Lv X; Wu Y; Hu P; Su F; Gong C; Song E; Liu B; Liu Q
Oncotarget; 2015 Oct; 6(31):31944-57. PubMed ID: 26397135
[TBL] [Abstract][Full Text] [Related]
33. Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells.
Zhang X; Zhang B; Zhang P; Lian L; Li L; Qiu Z; Qian K; Chen A; Liu Q; Jiang Y; Cui J; Qi B
PLoS One; 2019; 14(5):e0217181. PubMed ID: 31120927
[TBL] [Abstract][Full Text] [Related]
34. Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance.
Bekele RT; Venkatraman G; Liu RZ; Tang X; Mi S; Benesch MG; Mackey JR; Godbout R; Curtis JM; McMullen TP; Brindley DN
Sci Rep; 2016 Feb; 6():21164. PubMed ID: 26883574
[TBL] [Abstract][Full Text] [Related]
35. Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.
Droog M; Nevedomskaya E; Kim Y; Severson T; Flach KD; Opdam M; Schuurman K; Gradowska P; Hauptmann M; Dackus G; Hollema H; Mourits M; Nederlof P; van Boven H; Linn SC; Wessels L; van Leeuwen FE; Zwart W
Cancer Res; 2016 Jul; 76(13):3773-84. PubMed ID: 27197147
[TBL] [Abstract][Full Text] [Related]
36. Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.
Tsuboi K; Kaneko Y; Nagatomo T; Fujii R; Hanamura T; Gohno T; Yamaguchi Y; Niwa T; Hayashi SI
J Steroid Biochem Mol Biol; 2017 Mar; 167():115-125. PubMed ID: 27888136
[TBL] [Abstract][Full Text] [Related]
37. Loss of Estrogen-Regulated
Zhang W; Wu M; Chong QY; Zhang M; Zhang X; Hu L; Zhong Y; Qian P; Kong X; Tan S; Li G; Ding K; Lobie PE; Zhu T
Cancer Res; 2018 Sep; 78(17):4915-4928. PubMed ID: 29945962
[TBL] [Abstract][Full Text] [Related]
38. Endonuclease FEN1 Coregulates ERα Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer.
Flach KD; Periyasamy M; Jadhav A; Dorjsuren D; Siefert JC; Hickey TE; Opdam M; Patel H; Canisius S; Wilson DM; Donaldson Collier M; Prekovic S; Nieuwland M; Kluin RJC; Zakharov AV; Wesseling J; Wessels LFA; Linn SC; Tilley WD; Simeonov A; Ali S; Zwart W
Cancer Res; 2020 May; 80(10):1914-1926. PubMed ID: 32193286
[TBL] [Abstract][Full Text] [Related]
39. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.
Ward A; Shukla K; Balwierz A; Soons Z; König R; Sahin O; Wiemann S
J Pathol; 2014 Aug; 233(4):368-79. PubMed ID: 24752803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
